TOP TEN perturbations for 38676_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38676_at
Selected probe(set): 202558_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38676_at (202558_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2
Relative Expression (log2-ratio):-4.1042213Number of Samples:2 / 2
| Experimental | keratinocyte differentiation study 2 (KLF4 siRNA) |
| KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency. | |
| Control | keratinocyte differentiation study 2 |
| Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):4.1005697Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):3.5970316Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (ductal and lobular carcinoma; primary)
Relative Expression (log2-ratio):3.4879894Number of Samples:2 / 4
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (ductal and lobular carcinoma; primary) |
| Primary tumor tissue samples obtained from the breast of patients with ductal and lobular carcinoma. |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (inflammatory carcinoma; primary)
Relative Expression (log2-ratio):3.4723692Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (inflammatory carcinoma; primary) |
| Primary tumor tissue samples obtained from the breast of patients with inflammatory carcinoma. |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):-3.4688616Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.3191671Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
engineered skin substitute study 2 (late) / engineered skin substitute study 1 (late)
Relative Expression (log2-ratio):-3.3079767Number of Samples:5 / 3
| Experimental | engineered skin substitute study 2 (late) |
| Human skin substitutes tissue samples collected after 42 and 56 days after transplantation to athymic mice. | |
| Control | engineered skin substitute study 1 (late) |
| Human skin substitutes tissue samples collected after 14 days in culture. |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (lobular carcinoma, NOS; primary)
Relative Expression (log2-ratio):3.2364159Number of Samples:2 / 39
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (lobular carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with lobular carcinoma (NOS). |
RhoA overexpr. study 1 (G14V) / mammary epithelial cell sample
Relative Expression (log2-ratio):-3.2247696Number of Samples:3 / 3
| Experimental | RhoA overexpr. study 1 (G14V) |
| Human mammary epithelial cells (hMEC) immortalized by retroviral transfection with a constitutively active RhoA mutant (G14V). Cells were cultivated in DFCI-I medium with 100ug/ml of G418. | |
| Control | mammary epithelial cell sample |
| Human mammary epithelial cells (hMEC) obtained during reduction mammoplasty. Cultivated in DFCI-I medium. |